Monitoring of leukemia stem cells in chronic myeloid leukemia patients

Leuk Lymphoma. 2018 Sep;59(9):2264-2266. doi: 10.1080/10428194.2017.1421755. Epub 2018 Jan 16.

Authors

Jieke Cui¹, Zunmin Zhu², Songya Liu³, Qing Li⁴, Li Meng³, Hui Cheng⁴, Zhaodong Zhong¹, Weiming Li¹, Yong You¹, Xiaojian Zhu³, Ping Zou¹

Affiliations

¹ a Institute of Hematology, Union Hospital , Tongji Medical College, Huazhong University of Science and Technology , Wuhan , P. R. China.
² b Department of Hematology , Henan Province People's Hospital , Zhengzhou , P. R. China.
³ c Department of Hematology , Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , P. R. China.
⁴ d Department of Hematology , Wuhan No.1 Hospital , Wuhan , P. R. China.

PMID: 29334838
DOI: 10.1080/10428194.2017.1421755

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Female
Fusion Proteins, bcr-abl / genetics*
Gene Expression Regulation, Leukemic / drug effects
Gene Expression Regulation, Leukemic / genetics*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Male
Middle Aged
Neoplastic Stem Cells / drug effects
Neoplastic Stem Cells / metabolism*
Neoplastic Stem Cells / pathology
Outcome Assessment, Health Care / methods
Outcome Assessment, Health Care / statistics & numerical data
Protein Kinase Inhibitors / therapeutic use
Remission Induction
Young Adult

Substances

BCR-ABL1 fusion protein, human
Protein Kinase Inhibitors
Fusion Proteins, bcr-abl